Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
102.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
↗
August 02, 2021
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi...
Via
Benzinga
A Preview Of Incyte's Earnings
↗
August 02, 2021
Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings...
Via
Benzinga
2 Stocks Under $100 You Can Buy and Hold Forever
↗
July 31, 2021
Drugmakers can be excellent long-term holdings.
Via
The Motley Fool
Eli Lilly-Incyte's Rheumatoid Arthritis Drug Gets OK From FDA For Solo Use In Hospitalized COVID-19 Patients
↗
July 29, 2021
The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid...
Via
Benzinga
FDA Strikes Off Incyte's Retifanlimab Application In Anal Cancer
↗
July 26, 2021
The
Via
Benzinga
Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
July 23, 2021
From
Incyte Corporation
Via
Business Wire
Benchmark Upgrades Incyte After Stock Selloff
↗
July 20, 2021
The recent downturn in Incyte Corporation’s (NASDAQ:INCY...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
↗
July 20, 2021
Upgrades For Bank of Marin Bancorp (NASDAQ:
Via
Benzinga
AbbVie, Lilly Atopic Dermatitis Treatments Hit With Further Delays With FDA
↗
July 16, 2021
AbbVie Inc (NYSE: ABBV) and Eli Lilly And Co (NYSE: LLY) will have to keep waiting for a chance for their JAK inhibitors in atopic dermatitis to see the market....
Via
Benzinga
Incyte to Report Second Quarter Financial Results
July 15, 2021
From
Incyte
Via
Business Wire
Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients
↗
July 15, 2021
Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM...
Via
Benzinga
Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease
July 14, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
↗
July 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,...
Via
Benzinga
Topics
Product Recall
BriaCell's Early-Stage Combination Study In Advanced Breast Cancer Starts Enrollment
↗
July 14, 2021
BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ:...
Via
Benzinga
Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
↗
July 09, 2021
The National Medical Products Administration (NMPA) of China has accepted for review Innovent Biologics Inc's (OTC: IVBIY) marketing application seeking...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
↗
July 01, 2021
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive...
Via
Benzinga
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
↗
June 29, 2021
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...
Via
Benzinga
FDA AdCom In Favor Of Delaying Incyte's Retifanlimab Approval In Anal Cancer
↗
June 25, 2021
Members of the Oncologic Drugs Advisory Committee
Via
Benzinga
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
From
Incyte
Via
Business Wire
Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
June 24, 2021
From
Incyte
Via
Business Wire
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
↗
June 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...
Via
Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
↗
June 20, 2021
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...
Via
Benzinga
How This Pharma Company Can Benefit From Its Competitors
↗
June 20, 2021
Delays in FDA approval for Incyte could spell good news for Sanofi.
Via
The Motley Fool
3 Promising Oncology Stocks To Consider Adding To Your Portfolio
↗
June 14, 2021
With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio.
Via
Talk Markets
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
June 12, 2021
From
Incyte
Via
Business Wire
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
June 11, 2021
From
Incyte Corporation
Via
Business Wire
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
June 08, 2021
From
Incyte
Via
Business Wire
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...
From
MorphoSys AG
Via
AccessWire
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
From
Incyte
Via
Business Wire
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
↗
June 02, 2021
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of...
Via
Benzinga
< Previous
1
2
...
18
19
20
21
22
23
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
